{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:24:07Z","timestamp":1776918247617,"version":"3.51.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s15010-018-1202-9","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T05:50:30Z","timestamp":1535953830000},"page":"7-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Vancomycin-resistant enterococci (VRE): a reason to isolate?"],"prefix":"10.1007","volume":"47","author":[{"given":"Maria J. G. T.","family":"Vehreschild","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Haverkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena M.","family":"Biehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Lemmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"F\u00e4tkenheuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,3]]},"reference":[{"key":"1202_CR1","unstructured":"ECDC. Surveillance atlas of infectious diseases. 2018. Accessed 16 Aug 2018."},{"key":"1202_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13756-018-0353-x","volume":"7","author":"C Remschmidt","year":"2018","unstructured":"Remschmidt C, et al. Continuous increase of vancomycin resistance in enterococci causing nosocomial infections in Germany\u201410\u00a0years of surveillance. Antimicrob Resist Infect Control. 2018;7:54.","journal-title":"Antimicrob Resist Infect Control"},{"key":"1202_CR3","unstructured":"Werner G, et al. Enterococcus faecium strains from bloodstream infections of German hospital patients revealed a preferred prevalence of ST117 and an increasing number of vanB-type VRE between 2011 and 2017. In: European Congress of Microbiology and Infectious Diseases, Madrid; 2018."},{"key":"1202_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1017\/ice.2017.248","volume":"39","author":"H McDermott","year":"2018","unstructured":"McDermott H, et al. Vancomycin-resistant enterococci (VRE) in the intensive care unit in a nonoutbreak setting: identification of potential reservoirs and epidemiological associations between patient and environmental VRE. Infect Control Hosp Epidemiol. 2018;39:40\u20135.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1202_CR5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3109\/10428194.2013.842983","volume":"55","author":"AE Rosko","year":"2014","unstructured":"Rosko AE, et al. Vancomycin-resistant enterococci infection: not just for the transplanted. Leuk Lymphoma. 2014;55:1320\u20135.","journal-title":"Leuk Lymphoma"},{"key":"1202_CR6","doi-asserted-by":"publisher","first-page":"e9000","DOI":"10.1097\/MD.0000000000009000","volume":"96","author":"CH Chen","year":"2017","unstructured":"Chen CH, et al. Clinical and microbiological characteristics of vancomycin-resistant Enterococcus faecium bloodstream infection in Central Taiwan. Medicine (Baltimore). 2017;96:e9000.","journal-title":"Medicine (Baltimore)"},{"key":"1202_CR7","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/cid\/cix232","volume":"64","author":"BJ Webb","year":"2017","unstructured":"Webb BJ, et al. Prediction of bloodstream infection due to vancomycin-resistant enterococcus in patients undergoing leukemia induction or hematopoietic stem-cell transplantation. Clin Infect Dis. 2017;64:1753\u20139.","journal-title":"Clin Infect Dis"},{"key":"1202_CR8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/cis580","volume":"55","author":"Y Taur","year":"2012","unstructured":"Taur Y, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:905\u201314.","journal-title":"Clin Infect Dis"},{"key":"1202_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/430909","volume":"41","author":"CA DiazGranados","year":"2005","unstructured":"DiazGranados CA, et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis. 2005;41:327\u201333.","journal-title":"Clin Infect Dis"},{"key":"1202_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/1471-2334-13-504","volume":"13","author":"SY Cho","year":"2013","unstructured":"Cho SY, et al. Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study. BMC Infect Dis. 2013;13:504.","journal-title":"BMC Infect Dis"},{"key":"1202_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13756-018-0335-z","volume":"7","author":"AA Mahony","year":"2018","unstructured":"Mahony AA, et al. Vancomycin-resistant Enterococcus faecium sequence type 796\u2014rapid international dissemination of a new epidemic clone. Antimicrob Resist Infect Control. 2018;7:44.","journal-title":"Antimicrob Resist Infect Control"},{"key":"1202_CR12","first-page":"791","volume":"14","author":"E Moulin","year":"2018","unstructured":"Moulin E, et al. Vancomycine-resistant enterococci (VRE): a new reality in our hospitals. Rev Med Suisse. 2018;14:791\u20134.","journal-title":"Rev Med Suisse"},{"key":"1202_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jhin.2010.11.008","volume":"77","author":"JH Wagenvoort","year":"2011","unstructured":"Wagenvoort JH, et al. Environmental survival of vancomycin-resistant Enterococcus faecium. J Hosp Infect. 2011;77:282\u20133.","journal-title":"J Hosp Infect"},{"key":"1202_CR14","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/jac\/dky074","volume":"73","author":"SJ Hal van","year":"2018","unstructured":"van Hal SJ, et al. Relentless spread and adaptation of non-typeable vanA vancomycin-resistant Enterococcus faecium: a genome-wide investigation. J Antimicrob Chemother. 2018;73:1487\u201391.","journal-title":"J Antimicrob Chemother"},{"key":"1202_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/1076629041310091","volume":"10","author":"KM Yeh","year":"2004","unstructured":"Yeh KM, et al. Vancomycin-resistant enterococcus (VRE) carriage and infection in intensive care units. Microb Drug Resist. 2004;10:177\u201383.","journal-title":"Microb Drug Resist"},{"key":"1202_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/JLP.JLP_32_17","volume":"10","author":"R Amberpet","year":"2018","unstructured":"Amberpet R, et al. Risk factors for intestinal colonization with vancomycin resistant enterococci\u2019 a prospective study in a level III pediatric intensive care unit. J Lab Physicians. 2018;10:89\u201394.","journal-title":"J Lab Physicians"},{"key":"1202_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s15010-012-0269-y","volume":"40","author":"BJ Liss","year":"2012","unstructured":"Liss BJ, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40:613\u20139.","journal-title":"Infection"},{"key":"1202_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3855\/jidc.4451","volume":"8","author":"H Gedik","year":"2014","unstructured":"Gedik H, et al. Vancomycin-resistant enterococci colonization and bacteremia in patients with hematological malignancies. J Infect Dev Ctries. 2014;8:1113\u20138.","journal-title":"J Infect Dev Ctries"},{"key":"1202_CR19","unstructured":"Biehl LM, Stemler HP, Gillis J, Peter M, D\u00f6rfel S, Vogel W, Kern WV, G\u00f6lz H, Bertz H, Rohde H, Klupp EM, Schafhausen P, Salmanton-Garc\u00eda J, Ertel J, Zweigner J, Seifert H, Vehreschild MJGT, Impact of single room contact precautions on hospital-acquisition and transmission of vancomycin-resistant enterococci in a high-risk setting: preliminary results from the CONTROL study||Oral #O0177 in 28th ECCMID, Madrid; 2018."},{"key":"1202_CR20","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.bbmt.2010.05.008","volume":"16","author":"M Kamboj","year":"2010","unstructured":"Kamboj M, et al. The changing epidemiology of vancomycin-resistant enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant. 2010;16:1576\u201381.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1202_CR21","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.3109\/10428194.2014.1003557","volume":"56","author":"MC Ornstein","year":"2015","unstructured":"Ornstein MC, et al. Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. Leuk Lymphoma. 2015;56:2536\u201342.","journal-title":"Leuk Lymphoma"},{"key":"1202_CR22","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/bmt.2014.150","volume":"49","author":"M Tavadze","year":"2014","unstructured":"Tavadze M, et al. Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49:1310\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"1202_CR23","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/cid\/cis550","volume":"55","author":"J Vydra","year":"2012","unstructured":"Vydra J, et al. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:764\u201370.","journal-title":"Clin Infect Dis"},{"key":"1202_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1017\/ice.2014.3","volume":"36","author":"CD Ford","year":"2015","unstructured":"Ford CD, et al. Frequency, risk factors, and outcomes of vancomycin-resistant enterococcus colonization and infection in patients with newly diagnosed acute leukemia: different patterns in patients with acute myelogenous and acute lymphoblastic leukemia. Infect Control Hosp Epidemiol. 2015;36:47\u201353.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1202_CR25","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/tid.12433","volume":"17","author":"CD Ford","year":"2015","unstructured":"Ford CD, et al. The clinical impact of vancomycin-resistant enterococcus colonization and bloodstream infection in patients undergoing autologous transplantation. Transpl Infect Dis. 2015;17:688\u201394.","journal-title":"Transpl Infect Dis"},{"key":"1202_CR26","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.3109\/10428194.2014.896007","volume":"55","author":"MJ Satlin","year":"2014","unstructured":"Satlin MJ, et al. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leuk Lymphoma. 2014;55:2858\u201365.","journal-title":"Leuk Lymphoma"},{"key":"1202_CR27","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/tid.12612","volume":"18","author":"M Hefazi","year":"2016","unstructured":"Hefazi M, et al. Vancomycin-resistant enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transpl Infect Dis. 2016;18:913\u201320.","journal-title":"Transpl Infect Dis"},{"key":"1202_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2047-2994-1-9","volume":"1","author":"S Fournier","year":"2012","unstructured":"Fournier S, Brun-Buisson C, Jarlier V. Twenty years of antimicrobial resistance control programme in a regional multi hospital institution, with focus on emerging bacteria (VRE and CPE). Antimicrob Resist Infect Control. 2012;1:9.","journal-title":"Antimicrob Resist Infect Control"},{"key":"1202_CR29","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1207290","volume":"368","author":"SS Huang","year":"2013","unstructured":"Huang SS, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;368:2255\u201365.","journal-title":"N Engl J Med"},{"key":"1202_CR30","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1017\/ice.2016.156","volume":"37","author":"EM Martin","year":"2016","unstructured":"Martin EM, et al. Elimination of routine contact precautions for endemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: a retrospective quasi-experimental study. Infect Control Hosp Epidemiol. 2016;37:1323\u201330.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1202_CR31","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.ajic.2017.06.017","volume":"45","author":"AC Bardossy","year":"2017","unstructured":"Bardossy AC, et al. Evaluation of contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. Am J Infect Control. 2017;45:1369\u201371.","journal-title":"Am J Infect Control"},{"key":"1202_CR32","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1017\/ice.2018.57","volume":"39","author":"G Bearman","year":"2018","unstructured":"Bearman G, et al. Impact of discontinuing contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: an interrupted time series analysis. Infect Control Hosp Epidemiol. 2018;39:676\u201382.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"1202_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ajic.2017.08.031","volume":"46","author":"AR Marra","year":"2018","unstructured":"Marra AR, et al. Discontinuing contact precautions for multidrug-resistant organisms: a systematic literature review and meta-analysis. Am J Infect Control. 2018;46:333\u201340.","journal-title":"Am J Infect Control"},{"key":"1202_CR34","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijid.2010.05.002","volume":"14","author":"RP Wenzel","year":"2010","unstructured":"Wenzel RP, Edmond MB. Infection control: the case for horizontal rather than vertical interventional programs. Int J Infect Dis. 2010;14:S3\u2013S5.","journal-title":"Int J Infect Dis"},{"key":"1202_CR35","doi-asserted-by":"publisher","first-page":"eaar6115","DOI":"10.1126\/scitranslmed.aar6115","volume":"10","author":"SJ Pidot","year":"2018","unstructured":"Pidot SJ, et al. Increasing tolerance of hospital Enterococcus faecium to handwash alcohols. Sci Transl Med, 2018;10:eaar6115. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aar6115\n                    \n                  .","journal-title":"Sci Transl Med"},{"key":"1202_CR36","doi-asserted-by":"publisher","first-page":"S0195\u20136701(18)3","DOI":"10.1016\/j.jhin.2018.02.016","volume":"21","author":"FNJ Frakking","year":"2018","unstructured":"Frakking FNJ, et al. Recommendations for the successful control of a large outbreak of vancomycin-resistant Enterococcus faecium in a non-endemic hospital setting. J Hosp Infect. 2018;21:S0195\u20136701(18)30109\u20139. \n                    https:\/\/doi.org\/10.1016\/j.jhin.2018.02.016\n                    \n                  .","journal-title":"J Hosp Infect"},{"key":"1202_CR37","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1001\/jama.290.14.1899","volume":"290","author":"HT Stelfox","year":"2003","unstructured":"Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA. 2003;290:1899\u2013905.","journal-title":"JAMA"},{"key":"1202_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajic.2008.04.257","volume":"37","author":"DJ Morgan","year":"2009","unstructured":"Morgan DJ, et al. Adverse outcomes associated with contact precautions: a review of the literature. Am J Infect Control. 2009;37:85\u201393.","journal-title":"Am J Infect Control"},{"key":"1202_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jhin.2010.04.027","volume":"76","author":"C Abad","year":"2010","unstructured":"Abad C, Fearday A, Safdar N. Adverse effects of isolation in hospitalised patients: a systematic review. J Hosp Infect. 2010;76:97\u2013102.","journal-title":"J Hosp Infect"},{"key":"1202_CR40","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1017\/ice.2018.93","volume":"39","author":"EM Martin","year":"2018","unstructured":"Martin EM, et al. Noninfectious hospital adverse events decline after elimination of contact precautions for MRSA and VRE. Infect Control Hosp Epidemiol. 2018;39:788\u201396.","journal-title":"Infect Control Hosp Epidemiol"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-018-1202-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-018-1202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-018-1202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T07:19:00Z","timestamp":1568704740000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-018-1202-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,3]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1007\/s15010-018-1202-9","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,3]]},"assertion":[{"value":"18 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LMB has received lecture honoraria from Astellas and Merck\/MSD, and travel grants from 3M and Gilead. MJGTV is a consultant to: Alb-Fils Kliniken GmbH, Arderypharm, Astellas Pharma, Berlin Chemie, DaVolterra, MaaT Pharma and Merck\/MSD; has served at the speakers\u2019 bureau of: Astellas Pharma, Basilea, Gilead Sciences, Merck\/MSD, Organobalance, Pfizer; received research funding from: 3M, Astellas Pharma, DaVolterra, Gilead Sciences, MaaT Pharma, Merck\/MSD, Morphochem, Organobalance, Seres Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}